MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$50,444K
Free Cash flow
-$14,529K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Maturity of short-term investmen...
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Payment of pipe financing relate...
Discount amortization on short-t...
Deferred offering costs paid for...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-16,640
-22,194
-23,251
2,655
Share-based compensation expense
1,520
2,193
2,388
2,718
Gain on sale of business
0
0
0
87,266
Discount amortization on short-term investments
359
347
831
717
Non-cash interest expense
-
-
-
0
Non-cash lease expense
0
0
0
0
Depreciation and amortization expense
-
-
79
-
Depreciation expense
1
-77
-
5
Accounts receivable
0
0
0
0
Inventory
0
0
0
0
Prepaid expenses and other current assets
-755
-1,470
375
965
Other non-current assets
-162
-163
-163
-165
Operating lease liabilities
0
0
0
0
Accounts payable and accrued liabilities
32
-3,494
4,671
985
Other liabilities
0
0
0
0
Net cash used in operating activities
-14,529
-22,208
-17,234
-15,378
Proceeds from sale of business, net cash, cash equivalents, and restricted cash
0
0
0
-70
Purchases of property and equipment
0
0
0
0
Purchase of short-term investments
50,635
19,186
22,918
93,555
Maturity of short-term investments
33,768
38,616
39,764
1,998
Net cash provided by investing activities
-16,867
19,430
16,846
-91,627
Proceeds from sale of common stock and prefunded warrants in pipe financing
87,500
0
0
0
Proceeds from issuance of common stock under employee stock purchase plan
28
-
25
0
Issuance of common stock upon exercise of stock options
56
0
0
0
Payment of pipe financing related transaction costs
5,654
0
0
0
Deferred offering costs paid for financing
90
-
0
0
Net cash provided by financing activities
81,840
0
25
0
Net increase in cash and cash equivalents
50,444
-2,778
-363
-107,005
Cash, cash equivalents and restricted cash, beginning of period
34,790
37,568
37,931
28,734
Cash and cash equivalents, end of period
85,234
34,790
37,568
37,931
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock and...
$87,500K
(-12.50%↓ Y/Y)
Issuance of common stock
upon exercise of...
$56K
(115.38%↑ Y/Y)
Proceeds from issuance of
common stock under...
$28K
(16.67%↑ Y/Y)
Net cash provided by
financing activities
$81,840K
(-13.26%↓ Y/Y)
Canceled cashflow
$5,744K
Net increase in cash
and cash...
$50,444K
(-56.59%↓ Y/Y)
Canceled cashflow
$31,396K
Payment of pipe
financing related...
$5,654K
(0.52%↑ Y/Y)
Deferred offering costs
paid for financing
$90K
(18.42%↑ Y/Y)
Maturity of short-term
investments
$33,768K
(86.74%↑ Y/Y)
Share-based compensation
expense
$1,520K
(-68.11%↓ Y/Y)
Prepaid expenses and
other current assets
-$755K
(16.67%↑ Y/Y)
Other non-current
assets
-$162K
(-121.15%↓ Y/Y)
Accounts payable and
accrued liabilities
$32K
(101.85%↑ Y/Y)
Depreciation expense
$1K
(-98.63%↓ Y/Y)
Net cash provided by
investing activities
-$16,867K
(-119.46%↓ Y/Y)
Net cash used in
operating activities
-$14,529K
(77.59%↑ Y/Y)
Canceled cashflow
$33,768K
Canceled cashflow
$2,470K
Purchase of short-term
investments
$50,635K
(57.18%↑ Y/Y)
Net (loss) income
-$16,640K
Discount amortization on
short-term investments
$359K
(1809.52%↑ Y/Y)
Buy us a coffee
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)